Skip to main content
SpringerLink
Log in

Finding cost-effective treatment options in mCRPC

  • Meeting report
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study was funded by Astellas Pharma, Inc., and Medivation, Inc., USA.

  2. The study was funded by Astellas Pharma, Inc., and Medivation, Inc., USA.

  3. The study received financial support from Janssen Cilag SA, Colombia.

References

  1. Duran A, et al. Number Needed to Treat and Associated Incremental Costs of Treatment with Enzalutamide Versus Abiraterone Acetate plus Prednisone in Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer in Spain and the United Kingdom. 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PCN113, 20 May 2017. Available from: URL: https://www.ispor.org/ScientificPresentationsDatabase/Presentation/71875?pdfid=49446.

  2. Okumura H, et al. Cost-Effectiveness Analysis of Enzalutamide for Patients with Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer in Japan. 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PCN114, 20 May 2017. Available from: URL: https://www.ispor.org/ScientificPresentationsDatabase/Presentation/71857?pdfid=49435.

  3. Gamboa O, et al. A Cost Comparison of Treatment with Abiraterone Acetate plus Prednisone in the Pre-Chemotherapy Setting Followed by Enzalutamide in the Post-Chemotherapy Setting Versus the Opposite Treatment Sequence in Metastatic Castration Resistant Prostate Cancer Patients with Non-Visceral Metastases in Colombia. 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PCN75, 20 May 2017. Available from: URL: https://www.ispor.org/ScientificPresentationsDatabase/Presentation/73591?pdfid=49489.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Finding cost-effective treatment options in mCRPC. PharmacoEcon Outcomes News 780, 17 (2017). https://doi.org/10.1007/s40274-017-4069-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-4069-6

Search

Navigation